FLAT GLASS (06865) intends to invest approximately 60.0399 million yuan to acquire 60% of Shanghai Fulai Ruicheng's equity.
Fenglight Glass (06865) announced that on August 5, 2026, the company signed a share transfer agreement with Yihe Investment, in which the company intends to sell 60% of the equity of Shanghai Fulairicheng to Yihe Investment for a total transaction price of approximately RMB 60.0399 million. Upon completion of the acquisition, Shanghai Fulairicheng will become a wholly-owned subsidiary of the company, and its financial data will be included in the company's consolidated financial statements.
FLAT GLASS (06865) announced that on August 5, 2026, the company signed a share transfer agreement with Yihe Investment. The company plans to acquire a 60% stake in Shanghai Fulairicheng from Yihe Investment, with a total transaction price of approximately RMB 60.0399 million. Upon completion of the acquisition, Shanghai Fulairicheng will become a wholly-owned subsidiary of the company, and its financial data will be included in the company's consolidated financial statements.
Strategically, this acquisition will grant the company complete strategic autonomy, allowing it to independently determine the research and development direction, market strategy, and resource allocation for Shanghai Fulairicheng, fully aligning it with the overall strategy of the group. Moreover, the limited synergies under the current equity participation will upgrade to business integration, enabling Shanghai Fulairicheng's research and development, sales, and other aspects to seamlessly integrate into the existing business system of the company, achieving a smooth transition from new materials R&D to mass production. On the business front, Shanghai Fulairicheng focuses on the R&D of new material technologies, technical glass products, functional glass, and new optical materials. Its R&D direction and pace can be directly controlled by the company, ensuring that technological results prioritize the upgrade of its own products.
Related Articles

JIANGSU EXPRESS (00177) has completed the issuance of 590 million yuan in super short-term financing bonds.

CSPC PHARMA (01093) received a $10 million milestone payment from AstraZeneca under the strategic research and development cooperation agreement.

SOCAM DEV (00983) issued a positive profit alert, anticipating a net profit attributable to shareholders of approximately HKD 28 million to HKD 33 million for the interim period, compared to a loss in the same period last year.
JIANGSU EXPRESS (00177) has completed the issuance of 590 million yuan in super short-term financing bonds.

CSPC PHARMA (01093) received a $10 million milestone payment from AstraZeneca under the strategic research and development cooperation agreement.

SOCAM DEV (00983) issued a positive profit alert, anticipating a net profit attributable to shareholders of approximately HKD 28 million to HKD 33 million for the interim period, compared to a loss in the same period last year.

RECOMMEND





